Biogen nets $592M in Boston real estate sale as cost-cutting campaign rolls on

A game of real estate musical chairs is underway in Kendall Square as Biogen hands the deed from one of its East Coast sites to office aficionado Boston Properties (BXP).

Wednesday, the Big Biotech and BXP—which bills itself as the largest publicly traded developer, owner and manager of swanky U.S. workplaces—wrapped up a $592 million sale of Biogen’s lab and life sciences property in the heart of Cambridge.